Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3295112rdf:typepubmed:Citationlld:pubmed
pubmed-article:3295112lifeskim:mentionsumls-concept:C0001818lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C0011570lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C0020934lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:3295112lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:3295112pubmed:issue6lld:pubmed
pubmed-article:3295112pubmed:dateCreated1987-7-21lld:pubmed
pubmed-article:3295112pubmed:abstractTextThirty-seven patients participating in a controlled treatment study with imipramine were classified as high or low depressed simultaneously on two depression measures. Analysis of variance by 2 (high-low depressed) X 2 (high-low imipramine dosage) groupings revealed significant dose but no depression main effects. The greater dose effect observed in the low depressed group and the greater response rates found among high-dose patients with low initial depression strongly suggest that the beneficial effect of imipramine in agoraphobia was not primarily antidepressant in nature.lld:pubmed
pubmed-article:3295112pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3295112pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3295112pubmed:languageenglld:pubmed
pubmed-article:3295112pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3295112pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3295112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3295112pubmed:statusMEDLINElld:pubmed
pubmed-article:3295112pubmed:monthJunlld:pubmed
pubmed-article:3295112pubmed:issn0022-3018lld:pubmed
pubmed-article:3295112pubmed:authorpubmed-author:Mavissakalian...lld:pubmed
pubmed-article:3295112pubmed:issnTypePrintlld:pubmed
pubmed-article:3295112pubmed:volume175lld:pubmed
pubmed-article:3295112pubmed:ownerNLMlld:pubmed
pubmed-article:3295112pubmed:authorsCompleteYlld:pubmed
pubmed-article:3295112pubmed:pagination358-61lld:pubmed
pubmed-article:3295112pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:meshHeadingpubmed-meshheading:3295112-...lld:pubmed
pubmed-article:3295112pubmed:year1987lld:pubmed
pubmed-article:3295112pubmed:articleTitleInitial depression and response to imipramine in agoraphobia.lld:pubmed
pubmed-article:3295112pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3295112pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3295112pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed